Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Sunethra Wimalasundera"'
Autor:
Navita L. Mallalieu, Sunethra Wimalasundera, Joy C. Hsu, Wendy Douglass, Chris Wells, Inmaculada Calvo Penades, Ruben Cuttica, Hans-Iko Huppertz, Rik Joos, Yukiko Kimura, Diana Milojevic, Margalit Rosenkranz, Kenneth Schikler, Tamas Constantin, Carine Wouters
Publikováno v:
Pediatric Rheumatology Online Journal, Vol 17, Iss 1, Pp 1-10 (2019)
Abstract Background The anti–interleukin-6 receptor-alpha antibody tocilizumab was approved for intravenous (IV) injection in the treatment of patients with systemic juvenile idiopathic arthritis (sJIA) aged 2 to 17 years based on results of a rand
Externí odkaz:
https://doaj.org/article/7f02982439724267a0d9a1e6ca5fa34f
Autor:
Ruben Cuttica, Rik Joos, Hermine I. Brunner, Yukiko Kimura, Zbigniew Zuber, Manuel Ferrandiz Zavaler, Nicolino Ruperto, Kamal N. Bharucha, Fabrizio De Benedetti, Sunethra Wimalasundera, Ruben Burgos-Vargas, Inmaculada Calvo Penades, Graciela Espada, Wendy Douglass, Alberto Martini, Vladimir Keltsev, Chris Wells, Earl D. Silverman, Ricardo Machado Xavier, Chantal Job-Deslandre, Daniel J. Lovell, Carolina Duarte
Publikováno v:
Arthritis & Rheumatology (Hoboken, N.j.)
Objective To report the 2‐year efficacy and safety of tocilizumab (TCZ) in patients with polyarticular‐course juvenile idiopathic arthritis (JIA). Methods Patients ages 2–17 years with active polyarticular‐course JIA, in whom treatment with m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b134ea905446bbdd96810445ac41b0d6
http://europepmc.org/articles/PMC7986602
http://europepmc.org/articles/PMC7986602
Autor:
Jordi Anton, Navita L. Mallalieu, Heinrike Schmeling, Gerd Horneff, Fabrizio De Benedetti, Inmaculada Calvo Penades, Alina Boteanu, Kabita Nanda, Daniel J. Lovell, Min Bao, Kamal N. Bharucha, Nicolino Ruperto, Michael Henrickson, Sunethra Wimalasundera, Johannes Roth, Manuela Pardeo, Jennifer E. Weiss, Athimalaipet V Ramanan, Nadina Rubio-Pérez, Wendy Douglass, Alberto Martini, Chris Wells, Joy C. Hsu, Hermine I. Brunner, Kirsten Minden, Markus Hufnagel, Ruben Cuttica
Publikováno v:
Rheumatology (Oxford, England)
Objectives To determine s.c. tocilizumab (s.c.-TCZ) dosing regimens for systemic JIA (sJIA) and polyarticular JIA (pJIA). Methods In two 52-week phase 1 b trials, s.c.-TCZ (162 mg/dose) was administered to sJIA patients every week or every 2 weeks (e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::20149b973cfa7dd18ad97a9a635829fa
http://europepmc.org/articles/PMC8487273
http://europepmc.org/articles/PMC8487273
Autor:
Ruben Cuttica, Rik Joos, Hans-Iko Huppertz, Chris Wells, Diana Milojevic, Joy C. Hsu, Kenneth N. Schikler, Tamás Constantin, Wendy Douglass, Sunethra Wimalasundera, Yukiko Kimura, Inmaculada Calvo Penades, Navita L. Mallalieu, Margalit Rosenkranz, Carine Wouters
Publikováno v:
Pediatric Rheumatology Online Journal
Pediatric Rheumatology Online Journal, Vol 17, Iss 1, Pp 1-10 (2019)
Pediatric Rheumatology Online Journal, Vol 17, Iss 1, Pp 1-10 (2019)
Background The anti–interleukin-6 receptor-alpha antibody tocilizumab was approved for intravenous (IV) injection in the treatment of patients with systemic juvenile idiopathic arthritis (sJIA) aged 2 to 17 years based on results of a randomized co
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d9ab131b2a064fbb539cdacd8c6a956a
https://pubmed.ncbi.nlm.nih.gov/31438986
https://pubmed.ncbi.nlm.nih.gov/31438986
Autor:
Navita L. Mallalieu, Kirsten Minden, Ruben Cuttica, Alberto Martini, N Ruperto, Hermine I. Brunner, Jennifer E. Weiss, Gerd Horneff, Markus Hufnagel, Fabrizio De Benedetti, Wendy Douglass, Daniel J. Lovell, Chris Wells, Sunethra Wimalasundera, Jordi Anton, Heinrike Schmeling, Athimalaipet V Ramanan, María Luz Gámir-Gámir, Michael Henrickson
Publikováno v:
Rheumatology. 58
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c5a1d1d07d863a1319d30a9d81a4fa5d
https://doi.org/10.1093/rheumatology/kez108.078
https://doi.org/10.1093/rheumatology/kez108.078
Autor:
Navita Mallalieu, Sunethra Wimalasundera, Hsu, Joy, Douglass, Wendy, Wells, Chris, Penades, Inmaculada, Cuttica, Ruben, Hans-Iko Huppertz, Joos, Rik, Kimura, Yukiko, Milojevic, Diana, Rosenkranz, Margalit, Schikler, Kenneth, Constantin, Tamas, Wouters, Carine
Appendix 1. List of investigators and institutional review boards or ethics committees. Appendix 2. Calculation of sample size. Appendix 3. Details of patients with hypersensitivity reactions. (DOCX 59 kb)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c49e15148a9502ea267a1f7a8b1b51e
Autor:
Margalit Rosenkranz, Carine Wouters, Hans Iko Huppertz, Sunethra Wimalasundera, Ruben Cuttica, Yukiko Kimura, I. Calvo Penadés, Tamás Constantin, Rik Joos, Wendy Douglass, Chris Wells, D. Milojevic, Kenneth N. Schikler
Publikováno v:
THURSDAY, 14 JUNE 2018.
Background Intravenous (IV) tocilizumab (TCZ) was approved in the, US (2011), EU (2013) and other countries for the treatment of systemic juvenile idiopathic arthritis (sJIA) patients (pts)≥2 years of age, based on a phase 3 study WA18221.1 US Food
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7446aeb837630834a260412952e54339
https://doi.org/10.1136/annrheumdis-2018-eular.2628
https://doi.org/10.1136/annrheumdis-2018-eular.2628
Autor:
Fabrizio De Benedetti, AK Kadva, Kamal N. Bharucha, Sunethra Wimalasundera, Navita L. Mallalieu, Hermine I. Brunner, J Weiss, Kirsten Minden, Nicolino Ruperto, Ruchi Upmanyu, Michael Henrickson, Jordi Anton, Heinrike Schmeling, Ruben Cuttica, Athimalaipet V Ramanan, Alberto Martini, Daniel J. Lovell, Shazad Jafri, Joy C. Hsu
Publikováno v:
Rheumatology. 56
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b2c60157a42608e1ce0c29d87e996888
https://doi.org/10.1093/rheumatology/kex356.052
https://doi.org/10.1093/rheumatology/kex356.052
Autor:
Rik Joos, Joy C. Hsu, Navita L. Mallalieu, Ruben Cuttica, Sunethra Wimalasundera, Kenneth N. Schikler, D. Milojevic, K Wang, Hans Iko Huppertz, Margalit Rosenkranz, Chris Wells, Carine Wouters, I. Calvo Penadés, Yukiko Kimura, Tamás Constantin
Publikováno v:
Oral Presentations.
Background Tocilizumab (TCZ) is approved for the treatment of systemic juvenile idiopathic arthritis (sJIA) based on clinical trials in patients (pts) ≥2 years of age. This study (NP25737) is the first for a biologic in sJIA pts Objectives To evalu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7ee319aff1865e1441d223d747f33a6f
https://doi.org/10.1136/annrheumdis-2017-eular.2386
https://doi.org/10.1136/annrheumdis-2017-eular.2386